Published in Support Care Cancer on January 04, 2015
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain (2001) 16.05
Breakthrough pain: definition, prevalence and characteristics. Pain (1990) 3.35
Breakthrough pain: characteristics and impact in patients with cancer pain. Pain (1999) 2.53
The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain (2008) 2.48
Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer (2002) 2.01
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med (2004) 1.71
Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage (2000) 1.59
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain (2006) 1.38
Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol (2007) 1.18
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin (2009) 1.13
Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain (2003) 1.11
Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer (2009) 1.11
Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage (2011) 1.01
Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain. J Pain Symptom Manage (2012) 0.99
Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect. Cancer (1992) 0.98
Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag (2010) 0.98
Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin (2011) 0.97
Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin (2011) 0.96
Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag (2010) 0.91
Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med (2007) 0.84
Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain. Eur J Pain (2014) 0.78
Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. J Opioid Manag (2011) 0.77
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol (2012) 3.26
Opioid prescription in Italy: new law, no effect. Lancet (2002) 2.01
Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol (2012) 1.93
Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage (2002) 1.91
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer (2003) 1.72
[Hybrid, perventricular closure of muscular ventricular septal defects]. Kardiol Pol (2012) 1.55
Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract (2010) 1.53
Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf (2003) 1.47
Opioids for chronic non-cancer pain: a critical view from the other side of the pond. Minerva Anestesiol (2015) 1.39
CT-guided neurolytic splanchnic nerve block by an anterior approach. J Pain Symptom Manage (2002) 1.39
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem (2002) 1.36
Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage (2013) 1.32
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health (2013) 1.22
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol (2004) 1.16
Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain (2008) 1.04
[For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres]. Bull Cancer (2004) 1.03
Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain. J Pain Symptom Manage (2012) 0.99
The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesth Analg (2004) 0.98
Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin (2012) 0.97
Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J Invest Dermatol (2002) 0.95
Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain (2010) 0.94
Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology (2008) 0.94
The effects of remifentanil and gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers. Anesth Analg (2004) 0.92
Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage (2007) 0.91
The absence of acute tolerance during remifentanil infusion in volunteers. Anesth Analg (2002) 0.89
Frequency of side effects in outpatient cancer care and their influence on patient satisfaction--a prospective survey using the PASQOC questionnaire. Support Care Cancer (2008) 0.89
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician (2014) 0.89
Gabapentin in painful ophthalmoplegia. J Pain Symptom Manage (2002) 0.89
S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. J Dtsch Dermatol Ges (2013) 0.88
How to use octreotide for malignant bowel obstruction. J Support Oncol (2004) 0.86
Incidence of chronic pain in patients with end-stage renal disease on dialysis. J Pain Symptom Manage (2005) 0.86
The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin (2009) 0.85
Circumstances of death in hospitalized patients and nurses' perceptions: French multicenter Mort-a-l'Hôpital survey. Arch Intern Med (2008) 0.85
Treatment strategies for cancer patients with breakthrough pain. Expert Opin Pharmacother (2009) 0.83
Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. Life Sci (2004) 0.83
Subcutaneous target stimulation (STS) in chronic noncancer pain: a nationwide retrospective study. Pain Pract (2010) 0.83
Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther (2009) 0.83
Breakthrough pain: on the road again. Eur J Pain (2009) 0.82
From Cork to Budapest by Skype: living and dying. BMJ Support Palliat Care (2012) 0.81
Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage (2003) 0.81
The impact of a medical undergraduate student-selected module in palliative care. BMJ Support Palliat Care (2013) 0.81
Local anesthetics for breakthrough pain in patients receiving intrathecal treatment for cancer pain management. Anesth Analg (2005) 0.80
Prediction of patient survival by healthcare professionals in a specialist palliative care inpatient unit: a prospective study. Am J Hosp Palliat Care (2008) 0.80
Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw (2013) 0.80
Ketamine in the management of chronic pancreatic pain. J Pain Symptom Manage (2003) 0.80
The role of OROS hydromorphone in the management of cancer pain. Pain Pract (2009) 0.80
Emerging drugs for cancer-related pain. Support Care Cancer (2011) 0.79
The impact of an aging population on palliative care. J Pain Palliat Care Pharmacother (2013) 0.79
Withdrawal acute psychosis after corticosteroid discontinuation. J Pain Symptom Manage (2007) 0.79
Tracheal stent to repair tracheal laceration after a double-lumen intubation. Ann Thorac Surg (2012) 0.78
Surgical treatment of early breast cancer in day surgery. Chir Ital (2007) 0.78
A review of the pharmacokinetic profile of transmucosal fentanyl formulations. Curr Med Res Opin (2012) 0.78
Mycoplasma bovis isolated from brain tissue of calves. Vet Rec (2005) 0.78
[What's new in the treatment of cancer pain?]. Bull Cancer (2004) 0.78
4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility. Anesth Analg (2004) 0.78
Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention. J Pain Symptom Manage (2005) 0.77
Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage (2002) 0.77
Localization of the sentinel lymph node in breast cancer: prospective comparison of vital staining and radioactive tracing methods. Chir Ital (2004) 0.77
Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids. J Pharmacol Exp Ther (2005) 0.76
Clarifications on oxycodone-naloxone combination in cancer pain management. Support Care Cancer (2012) 0.76
[WINHO quality indicators for outpatient oncology care in Germany]. Z Evid Fortbild Qual Gesundhwes (2013) 0.76
Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ (2004) 0.75
Opioid consumption in Italy: industry is not necessarily business--look at the effects. J Pain Symptom Manage (2004) 0.75
Problematic discharge from hospital for patients prescribed opioids for cancer pain. J Pain Symptom Manage (2005) 0.75
Palliative care in advanced cancer patients: how and when? And where? Oncologist (2012) 0.75
The critical recommendation for the treatment of melanoma patients: primum nil nocere. J BUON (2007) 0.75
Sympathetic blocks and disease progression modifying pain mechanisms. Reg Anesth Pain Med (2003) 0.75
Salmonella in meats, water, fruit and vegetables as disclosed from testing undertaken by Food Business Operators in Ireland from 2005 to 2009. Ir Vet J (2012) 0.75
Opioids for chronic nonmalignant and neuropathic pain. Eur J Pain (2005) 0.75
Stop and go strategy for opioid switching requires flexibility. Eur J Cancer (2012) 0.75
Letter to the editor: pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet (2013) 0.75
Switching to methadone: 'ad libitum' or fixed dose ratio? Palliat Med (2004) 0.75
Looking for the role of NSAIDs in cancer pain. J Clin Oncol (2005) 0.75
Cancer pain--progress and ongoing issues in Europe. Pain Res Manag (2009) 0.75
Epidural treatment in advanced cancer patients. Anesth Analg (2004) 0.75
About pain, opioids, and dialysis. J Pain Symptom Manage (2007) 0.75
Cancer pain undertreatment and prognostic factors. Pain (2012) 0.75
The marvelous carousel of opioids. Expert Opin Drug Saf (2015) 0.75
[The use of extracorporeal life support and continuous venovenous haemodiafiltration in severe angiotensin converting enzyme inhibitor, calcium channel bloker and beta-blocker multidrug intoxication]. Przegl Lek (2013) 0.75
[The DREZ lesion as an effective treatment for chronic hypothetically post-herpetic neuropathic pain. Case report and review of literature]. Neurol Neurochir Pol (2003) 0.75
Switching from methadone to tapentadol for cancer pain. J Pain Symptom Manage (2012) 0.75
Advanced glycation end-products prepared in solution under high pressure contain epitopes distinct from those formed in the dry reaction at high temperature. Arch Immunol Ther Exp (Warsz) (2005) 0.75
Prolonged uncontrolled pain, psychological distress, and opioid escalation. J Pain Symptom Manage (2004) 0.75
Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families. Anesth Analg (2012) 0.75
Can a phone call be more effective than an intrathecal implanted pump? Support Care Cancer (2012) 0.75
Sexuality in patients with advanced cancer: a prospective study in a population admitted to an acute pain relief and palliative care unit. Am J Hosp Palliat Care (2011) 0.75
Bedside anesthesia for painful procedures in onco-hematology. J Palliat Med (2008) 0.75
Promoting palliative care is prerequisite to future integrity of a comprehensive humane medicine. Onkologie (2010) 0.75
Information transfer to out-of-hours co-operatives: a survey of general practitioners' views in relation to palliative patients. BMJ Support Palliat Care (2012) 0.75
Auditory symptoms as an unrecognized manifestation of opioid toxicity: two case reports. J Pain Palliat Care Pharmacother (2014) 0.75
Naloxone in treating central adverse effects during opioid titration for cancer pain. J Pain Symptom Manage (2003) 0.75
Protest and survive, the U.K. Construction Safety Campaign: a case study of workers' and victims' family action and legal and regulatory inaction on construction health and safety. Int J Occup Environ Health (2007) 0.75
Block of interdigital nerves for cancer pain. J Pain Symptom Manage (2002) 0.75
[Coordination of external care, an original supportive care component at the Gustave Roussy Institute]. Soins (2006) 0.75
Developing a nurse-led clinic for patients with Parkinson's disease. Aust Nurs Midwifery J (2014) 0.75
Noninvasive ventilation for the treatment of dyspnea as a bridge from intensive to end-of-life care. J Pain Symptom Manage (2009) 0.75